StemCell Therapy

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries' Data - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

According to the report, the global minimally invasive biopsy technologies market was valued at $924.8 million in 2018 and is anticipated to reach $4.03 billion by 2030. The global minimally invasive biopsy technologies market is expected to grow at a double-digit compound annual growth rate (CAGR) in the forecast period 2019-2030, aided primarily by the anticipated launch of novel minimally invasive biopsy technologies.

The rapidly growing incidences of cancer and other chronic inflammatory disorders are inciting the use of minimally invasive and real-time diagnostic methods for early detection. With better patient compliance and greater sensitivity, minimally invasive biopsy technologies such as liquid biopsy and optical biopsy are emerging as novel tools for the early detection and effective disease management. Additionally, several other technologies including brush biopsy, fine needle aspiration, breath biopsy, and pigmented lesion assays are considerably evolving to be used in the minimally invasive management of cancer.

The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine is driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.

North America is the leading contributor in the global minimally invasive biopsy technologies market and contributed approximately 62.06% to the global market value in 2018. This region is anticipated to grow at a CAGR of 11.25% during the forecast period 2019-2030 and to continue dominating the global market in 2030 as well. However, the European region is expected to grow at an impressive CAGR of 15.40% during the forecast period 2019-2030. The Asia-Pacific region contributed a share of 12.41% to the global market and is anticipated to grow at a CAGR of 14.65% during the forecast period 2019-2030.

Research Highlights

Optical biopsy expected to witness an impressive CAGR of 15.77% during the forecast period 2019-2030. Moreover, in terms of therapeutic application, prostate cancer is expected to witness an impressive growth at a CAGR of 14.97% during the forecast period 2019-2030.

Liquid biopsy is currently the largest shareholder in the global minimally invasive biopsy technologies market. This market dominance is largely attributed to the worldwide availability of a significant number of liquid biopsy technologies.

This market intelligence report provides a multi-dimensional view of the global minimally invasive biopsy technologies market in terms of market size and growth potential. This research report aims at answering various aspects of the global minimally invasive biopsy technologies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with the recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire global minimally invasive biopsy technologies market for 2018 and 2030.

This report is a meticulous compilation of the research of about 65 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of 9 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including that of Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc.

The answers to the following key questions can be derived from this report:

Key Topics Covered

Executive Summary

1 Product Definition1.1 Inclusions and Exclusions

2 Research Scope2.1 Scope of Work2.2 Key Questions Answered in the Report

3 Research Methodology3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology3.1.1 Primary Data Sources3.1.2 Secondary Data Sources3.1.3 Selection Criteria for Company Profiles

4 Industry Analysis4.1 Industry Ecosystem4.2 Regulatory Framework and Government Initiatives4.2.1 Liquid Biopsy: Regulatory Framework4.2.1.1 Liquid Biopsy: Regulations in the U.S.4.2.1.2 Liquid Biopsy: Regulations in Other Countries4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.4.2.2.2 Optical Biopsy and Other Technologies: Regulations in Europe4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries4.3 Patent Analysis4.3.1 Liquid Biopsy: Patent Analysis4.3.2 Optical Biopsy: Patent Analysis4.4 Physician's Perception

5 Competitive Landscape5.1 Key strategies and Developments5.1.1 Partnerships, Alliances, and Business Expansions5.1.2 New Offerings5.1.3 Funding Activities5.1.4 Procurement and Sales Agreements5.1.5 Regulatory and Legal Developments5.1.6 Mergers and Acquisitions5.2 Market Share Analysis5.2.1 Market Share Analysis: Global Liquid Biopsy Market5.2.2 Market Share Analysis: Global Optical Biopsy Market5.2.3 Market Share Analysis: Global Other Technologies Market5.3 Growth Share Analysis5.3.1 Growth Share Matrix (by Technology)5.3.2 Growth Share Matrix (by Therapeutic Application)5.3.3 Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-20306.1 Assumptions and Limitations6.2 Key Findings and Opportunity Assessment6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)6.3.2 Market Dynamics6.3.2.1 Overview6.3.2.2 Impact Analysis6.3.2.3 Market Drivers6.3.2.3.1 Rising Global Burden of Cancer6.3.2.3.2 Increasing Number of Cross-Industry Collaborations6.3.2.3.3 Growing Prominence of Precision Medicine6.3.2.4 Market Restraints6.3.2.4.1 Uncertain Regulatory Requirements6.3.2.4.2 Lack of Favorable Reimbursement Policies6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers6.3.2.5 Market Opportunities6.3.2.5.1 Business Expansion in Emerging Economies6.3.2.5.2 Integration of Artificial Intelligence (AI)6.3.2.5.3 Rising Number of Initiatives by the Government6.4 Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-20307.1 Overview7.2 Global Liquid Biopsy Market Scenario, 2018-20307.2.1 Principle and Advantages of Liquid Biopsy7.2.2 Key Findings and Opportunity Assessment7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)7.2.3.1 Market Dynamics7.2.3.1.1 Impact Analysis7.2.3.1.2 Market Drivers7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests7.2.3.1.2.2 Recent Product Launches and Approvals7.2.3.1.2.3 Strong Pipeline7.2.3.1.3 Market Restraints7.2.3.1.3.1 Uncertain Regulatory Requirements7.2.3.1.3.2 Lack of Adequate Reimbursement7.2.4 Global Liquid Biopsy Market Segmentation7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-20307.2.4.1.1 Overview7.2.4.1.2 Tests7.2.4.1.3 Kits and Consumables7.2.4.1.4 Instruments7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)7.2.4.2.1 Overview7.2.4.2.2 Circulating Tumor DNA (ctDNA)7.2.4.2.3 Circulating Tumor Cells (CTCs)7.2.4.2.4 Cell-Free DNA (cfDNA)7.2.4.2.5 Extracellular Vesicles and Others7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)7.2.4.3.1 Overview7.2.4.3.2 Treatment Monitoring7.2.4.3.3 Prognosis and Recurrence Monitoring7.2.4.3.4 Treatment Selection7.2.4.3.5 Diagnosis and Screening7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)7.2.4.4.1 Overview7.2.4.4.2 Lung Cancer7.2.4.4.3 Breast Cancer7.2.4.4.4 Prostate Cancer7.2.4.4.5 Colorectal Cancer7.2.4.4.6 Blood Cancer7.2.4.4.7 Other Types of Cancer7.2.4.4.8 Non-Oncology Applications7.3 Global Optical Biopsy Market Scenario, 2018-20307.3.1 Principle and Advantages of Optical Biopsy7.3.2 Key Findings and Opportunity Assessment7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)7.3.3.1 Market Dynamics7.3.3.1.1 Impact Analysis7.3.3.1.2 Market Drivers7.3.3.1.2.1 Recent Product Launches and Approvals7.3.3.1.2.2 Significant Number of Funding and Investments7.3.3.1.2.3 Anticipated Product Launches7.3.3.1.3 Market Restraints7.3.3.1.3.1 Lack of Favorable Reimbursement7.3.3.1.3.2 Stringent Regulatory Guidelines7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-20307.3.4.1 Overview7.3.4.2 Oncology7.3.4.3 Non-Oncology Applications7.4 Global Other Technologies Market Scenario, 2018-20307.4.1 Overview7.4.2 Key Findings and Opportunity Assessment7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)7.4.3.1 Market Dynamics7.4.3.1.1 Impact Analysis7.4.3.1.2 Market Drivers7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities7.4.3.1.2.2 Strong Product Pipeline7.4.3.1.3 Market Restraints7.4.3.1.3.1 Poor Reimbursement Scenario7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies7.4.4 Global Other Technologies Market, (by Therapeutic Application)7.4.4.1 Overview7.4.4.2 Lung Cancer7.4.4.3 Melanoma7.4.4.4 Thyroid Cancer7.4.4.5 Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-20308.1 Overview and Key Findings8.2 North America8.3 Europe8.4 Asia-Pacific8.5 Latin America and the Middle East8.6 Rest-of-the-World

9 Company Profiles9.1 Abcodia Ltd.9.2 Adaptive Biotechnologies9.3 Biocept, Inc.9.4 Caliber Imaging & Diagnostics9.5 Chronix Biomedical9.6 DermTech9.7 F. Hoffmann-La Roche Ltd.9.8 Guardant Health, Inc.9.9 Mauna Kea Technologies9.10 Myriad Genetics9.11 NeoGenomics Laboratories, Inc.9.12 Owlstone Medical Ltd.9.13 QIAGEN9.14 Thermo Fisher Scientific9.15 Veracyte, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3128v2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-minimally-invasive-biopsy-technologies-markets-2019-2030---a-4-billion-opportunity-with-focus-on-liquid-biopsy-optical-biopsy-and-brush-biopsy-pigmented-lesion-assays-and-breath-biopsy-301035982.html

SOURCE Research and Markets

Read more:
Global Minimally Invasive Biopsy Technologies Markets, 2019-2030 - A $4+ Billion Opportunity with Focus on Liquid Biopsy, Optical Biopsy, and Brush...

Heading into this year, I was passionate about getting a very important message in front of investors.

Source: Shutterstock

It was my thesis that the next decade would not only be the most innovative in history, but that the stock market would experience its largest gains ever.

The start of 2020 as brutal as it has been reminds me of 1990. Stocks had already been in a bull market for eight years when the ball dropped on 1989 and ushered in the new decade. Most experts believed the bull market was over and that the 1990s would be a lost decade.

Boy, were they wrong.

The 1990s went on to become one of the greatest decades for stocks. Little technology companies youd never heard of became household names. Dell Computer now Dell Technologies (NYSE:DELL) gained over 91,000% during the 1990s. The biggest gains of the decade were driven by a plethora of new technologies centered around the internet and personal computing.

Today, we are now three months into the 2020s and stocks are in a similar situation. We entered the decade on the back of a 10-year bull market, only to slide quickly into a bear market.

Most people dont realize this, but the Dow did something similar in 1990. It fell by 19.5% essentially a bear market to start the decade before powering higher. I believe we will look back at the current sell-off and see it as the last great buying opportunity before a booming decade.

The selling is creating buying opportunities in investment trends that wont slow due to the pandemic. In fact, they could even accelerate due to the changing global landscape. Lets take a look at a few

Robotics:According to the editorial board atScience Robotics, robots could be an alternative to humans when it comes to certain healthcare tasks. Especially during a pandemic. Robots could collect lab results, automate lab tests, and help disinfect the patient rooms. In China, it was deemed too dangerous for humans to make critical deliveries of medicine and food into infected areas, so the country turned to robots.

Genomics:The future of healthcare will be based on advances in both technology and medicine. The latter will rely on the field of genomics. In the coming decade, it will be the norm to have your genome sequenced. This information will help create personalized medicine for each patient, as well as help speed up the creation of new drugs.

The response to the coronavirus is a great example of how medicine is evolving. In 10 years, this type of pandemic would not be an issue. The combination of artificial intelligence (AI), quantum computing, and genomics would create a vaccine within days.

Tele-everything:The biggest change to our lives throughout this ordeal has been the self-isolation. Either through a government mandate or by choice, most people around the globe are staying inside and not going about their normal activities. This has led to a work-from-home, school-from-home, and even workout-from-home situation.

The companies behind this trend are here to stay. When the pandemic is over, people will go back to work, school, and their local fitness facilities. But the tele-everything trend is not going away. In some circumstances, it is more convenient than what we were accustomed to. Everything from software companies to one of my favorite stocks,Teladoc (NYSE:TDOC), to online education will be pushed to grow faster and quicker after the pandemic.

Even though a lot of the stocks in these trends have been beaten down in the last month, the trends themselves are not dead. Nothing I mean nothing in life goes straight up. When it comes to the stock market, the strongest trends will hit speed bumps but those bumps offer investors opportunities.

Let me be straight with you. If you want to be wealthy, you must buy into high-growth, long-term trends. And to make the BIG money you need to buy when everyone else is selling.

That day is today.

Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities.

More:
3 High-Growth Trends to Invest In Now - Investorplace.com

The current pandemic situation that the world is suffering due to the SARS-CoV-2 coronavirus is hopelessly transforming any forecast that would have been set for 2020 in most environments. Even more in the field of health, where efforts are being made to end this situation.

In the case of personalized medicine in Spain, this year they expected to solve technological, social, legal, ethical and healthcare challenges with the possible approval of a strategic plan by the Government, which has been analyzed by the Senate for more than two years with the collaboration of experts in the field. A long-awaited regulation that it is more than likely to delay again.

From the point of view of the investigation, advances were outlined in CRISPR / Cas9, a molecular tool to edit or correct the genome of a cell. Also in a more efficient and combined use of the so-called micas omics sciences: genomics, metabolomics, epigenomics, etc., which, even though they have been going for several years, are still at the dawn of their journey.

Companies like OncoDNA, a company specialized in precision medicine for the treatment and diagnosis of cancer, continue working to promote new advances in this last section. She has spent several years dedicated to carrying out genomic analysis of samples from cancer patients, tissue and blood (liquid biopsy), to offer more information on the genetic profile of each tumor to specialists and thus be able to determine the most appropriate therapy for the patient.

Over the past 12 months the number of genes analyzed has been expanded in their tests, arriving their OncoDEEP and OncoSTRAT & GO solid biopsy panels until 313 and even, combining tissue analysis with liquid biopsy in stage IV solid tumors. Incorporating new essential biomarkers to know the peculiarities that can occur in each patient.

Pending all the news

In the same way, researchers continue to be very aware of the different publications that are appearing in the most prestigious media in the world in the field of oncology to improve their services. An example of this were the changes adopted a few months ago in your OncoSTRAT & GO test.

This new version includes the study of germline mutations in the ATM, BRCA1 and BRCA2 genes, as well as other pathway genes involved in homologous recombination, which can also be treated with PARP inhibitors. A solution that is already available and that is especially useful in patients with ovarian, prostate, pancreas and triple negative breast cancer.

In laboratories, and with the collaboration of different hospitals and specialized cancer centers around the world, work is also being done on this combination of omics sciences, which could offer a much more individualized view of the molecular profile of each patient, thus improving their prospects of success against cancer. Even to turn them into an effective tool to predict and assume preventive intervention strategies.

More advances in big data

Processing large amounts of data it will also continue to be key in the field of personalized medicine. Increasingly, taking into account that the progressive evolution of the micas omics will require technologies that translate their results into a language understandable to healthcare professionals.

In the oncological case they begin to emerge computer applications capable of processing and translating in a very short time the large amount of genetic information that each genomic analysis offers us. As with OncoKDM, an intelligent online genomic interpretation platform that responds to the most immediate needs of oncologists, pathologists, and other specialists in molecular biology.

It is capable of bringing together all the information that has been collected about a patient, such as the results of any genomic technology, molecular pathology data or clinical information, analyzing and interpreting it effectively at a clinical and biological level in a few minutes. In this way, it facilitates the oncologists decision making when choosing the ideal therapy for the patient or searching for clinical trials available in their country of origin , explains Adriana Terrdez, director of OncoDNA in Spain and Portugal.

It is to be expected that solutions such as those of genomic tests or software and platforms for the processing and interpretation of genomic data continue to evolve in the future in order to improve cancer patient care and make the best decisions in each case. It is working day by day in order that the news arrive as soon as possible. Even in these uncertain times.

//

Visit link:
COVID-19 transforms the challenges of Personalized Medicine for 2020 - Explica

According to a new report published by Proficient Market, titled, Global Biochip Market by Product Type (DNA Chips Market, Lab-On-A-Chip Market, Protein Chips Market & other) and by End-Users/Application (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers, Academic & Research Institutes & Other) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 2027 The report has offered an all-inclusive analysis of the global biochip market taking into consideration all the crucial aspects like growth factors, constraints, market developments, top investment pockets, future prospects, and trends. At the start, the report lays emphasis on the key trends and opportunities that may emerge in the near future and positively impact the overall industry growth.

According to the report, Global Biochip Market in 2019 stood at USD 14 billion and is expected to reach USD 62.82 billion by 2027 growing at a CAGR of 20.63% from 2020 to 2027.

Get Free Sample PDF (including full TOC, Tables and Figures) of Biochip Market @ https://proficientmarket.com/sample/1183

A biochip is a collection of microarrays organized on a solid substrate, allowing thousands of complex biochemical reactions, to determine various biological data, for instance, decoding the genes in less time. The biochip-based analysis is primarily used for on-site diagnosis. Biochips also undergo other diagnostic applications such as microarray technique, microfluidic technologies, & biosensors. A biochip can also provide analytical data regarding organic molecules associated with the living organisms. It helps in identifying airborne toxins, environmental pollutants, gene sequences, & other biochemical constituents.

Biochip Market Key Players: The research study includes profiles of leading companies operating in the global biochip market. Key players profiled in the report include:

Abbott Laboratories Agilent Technologies PerkinElmer Inc. Fluidigm Corporation Illumina GE Healthcare Bio-Rad Laboratories Inc. Cepheid Inc. Thermo Fisher Scientific F. Hoffmann-La Roche AG.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://proficientmarket.com/buying-request/1183

Thermo Fisher Scientific Inc. completed the acquisition of Affymetrix Inc., a leading provider of cellular and genetic analysis products. This acquisition helped Thermo Fisher to strengthen its leadership in biosciences, as well as acquire new genetic analysis capabilities to better serve clinical and applied markets.

Drivers for the Global Biochip Market: The increased use of biochips due to increasing cancer treatment and diagnostics. Rise in personalized medicine, drug discovery and life science research, need for high speed diagnostics and increased government funding are some of the key factors driving the growth for global biochips market. In addition, increasing healthcare awareness is also fueling the growth of global biochips market. Thus all these factors led to boosting the growth of the biochips market.

Opportunities for the Global Biochip Market: Rapid growing application of biochips will drive the market growth during forecasted period. While the Technological advancements and new product launches in the market are witnessed to augment the growth of the biochips market in forthcoming years. However, Rising demand of biochips in developing countries is witnessed to increase the market share of biochips. Moreover the Increasing adoption of personalized medicines by households will also propel the growth of the biochips market. Thus, all these factors will provide lucrative opportunities for the growth of the biochips market.

Restrains for the Global Biochip Market: The Strict government regulatory guidelines related to biochips are hampering the growth of the market. While the High instrument costs will also restrain the growth of this market. Lack of proper knowledge about biochip technology is a prominent restraint lowering the demand for biochip products. The irregularities arriving in healthcare coverage around the world are also more likely to challenge the growth of biochips market. Variable cost and adoption of biochip technologies is likely to affect the personalisation of medicine, eventually lowering the revenues of the global biochips market. Thus all these factors are creating a negative impact at the growth of the biochip market.

Region Wise, Global Biochip Market Analysis: Report covers the region wise analysis, global Biochip market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, North America leads the global Biochip market share followed by Europe and Asia Pacific. While the North America leads the global Biochip market due to the factors such as presence of well-established players, advanced informatics infrastructure, presence of experts and skilled workforce, and ongoing genomic R & D practices on a large scale in the region. While the rising R & D investments in genomic research is driving the growth of the market. Moreover, growing awareness regarding genetic tests for disease risk assessment and prevention is anticipated to have a positive impact on the growth of the regional market..

Access Full Report, here: https://proficientmarket.com/report/1183/global-biochip-market

Global Biochip Market: Product analysisDNA Chips MarketGene ExpressionSNP GenotypingCancer Diagnosis & TreatmentGenomicsDrug DiscoveryAgricultural BiotechnologyLab-On-A-Chip MarketClinical DiagnosticsGenomicsIVD & POCProteomicsDrug DiscoveryProtein Chips MarketProteomicsExpression ProfilingDiagnosticsHigh-Throughput ScreeningDrug DiscoveryOther Cell ArraysTissue Arrays

On the basis of type DNA Chips Market, accounted for largest share of total revenue generated due to the increasing use of DNA chip products. The use of DNA chip has empowered the scientific community by enabling measurement of the expression levels of large numbers of genes simultaneously. A DNA chip involves an array of microscopic spots each carrying numerous single-stranded oligonucleotides and are widely being used in biomedical research activities. Thus due to its huge utilization led to the growth of this segment which is fueling the biochip market.

Global Biochip Market: Application analysisBiotechnology and Pharmaceutical CompaniesHospitals and Diagnostics CentersAcademic & Research InstitutesOther

The demand of Global Biochip Market is highest from Biotechnology and Pharmaceutical Companies due to the numerous features offered by it. The utilization rate of biochips in biotechnology and pharmaceutical companies was high. The hospitals & diagnostics is the second fastest growing segment due to the adoption of biochip in new drug discovery as well as in point-of-care diagnostics has increased the consumption of these biochips in hospitals & diagnostics centers. Thus all these factors led to increase usage of biochips in this sectors which is propelling the growth of the biochip market.

Global Biochip Market: Region analysisNorth America: U.S., Canada, MexicoEurope: U.K., France, Germany, Spain, Italy, Rest of EuropeAsia Pacific: China, Japan, South Korea, ASEAN, IndiaRest of Asia Pacific: Latin America, Brazil, Argentina, Colombia, Rest of L.A.Middle East and Africa: Turkey, GCC, UAE, South Africa, Rest of Middle East

The report can be customized as per client requirements. For further queries, you can contact us on [emailprotected] or +1-773-800-2974. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Read the full press release and latest news of this report, here: https://proficientmarket.com/press-release/1188/global-biochip-market

About Us:Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 (GMT Office Hours)USA: +17738002974Email: [emailprotected]Web: proficientmarket.com

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at [emailprotected].

WiredRelease

Visit WiredRelease's Website

Here is the original post:
Insights On The Global Biochip Market To 2027 Featuring Abbott Laboratories, Agilent Technologies, PerkinElmer Inc., Fluidigm Corporation, Illumina,...

Technological advancements and scientific breakthroughs have propelled the assessment of pathogenesis and fostered precision medicine industry. Precision medicine has become instrumental in alleviating suffering pertaining to medical care, owing to unintended side effects resulting from one-size-fits-all approach.

Rapid transformation towards precision medicine is also believed to reduce the cost of treatment by doing away with inapt treatment plans. Precision medicine has become pivotal in leveraging doctors to select treatments based on a genetic understanding of the patient's disease and creating a personalized treatment plan.

Genetic laboratory industry is believed to be using processing power, data, science and operators to enhance the results for costly and debilitating diseases. In terms of technology, big data is touted to set the trend in precision medicine market as the technology enables more precision and tailoring compared to linking diverse data sets to showcase casual pathways. Dependence of precision medicine on big data has propelled the biomedical research.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/671

Stakeholders have shown increased traction towards big data analytics for it complements clinical care and streamlines public health surveillance. Notably, big data has the ability to track and predict major outbreaks to boost public healthcare resources and disseminate healthcare message to patients using social media.

Profound deployment of sensing technologies has fared well for big data analytics. With soaring trend for implantable and wearing sensing has been in line with the increased bandwidth and improved microelectronics.

With the wealth of information to different disease, big data revolution has offered an opportunity to embrace AI and machine learning algorithms in the massive data set. Global Market Insights, Inc., predicts big data analytics market share to have been registered at 12% in 2019, citing influx of complex of data generating in healthcare sector.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/671

Recent advancements in technology indicate that stakeholders are increasingly using precision medicine in oncology. With neurological disorders being one of the leading causes of morbidity and disability globally, precision medicine has grown in significance. The disorder is expected to grow on the heels of increased life expectancy and population growth leading to economic burden and health issues.

Oncology has opened avenues for precision medicines as central nervous system (CNS) market share in 2019 was pegged at over 24%, mainly attributed to soaring prevalence of CNS disorders globally.

Use of precision medicine in healthcare IT companies will become more noticeable in the next five years owing to soaring demand for technologically advanced equipment for analysis, rapid integration and storage of patient data. In bid to push to the capabilities in data analysis, data acquisition, and analytics-based decision making, established technology players and startups are adopting precision medicine.

Several healthcare IT companies are offering operation and software tools for healthcare systems to adopt personalized medicine. Healthcare IT companies segment was pegged at around US$ 16 bn in 2019.

With the time ideal for disruption through strategic business model owing to changing healthcare dynamics, stakeholders are increasingly inclined towards infusing investment in MEA. Leading companies believe MEA to emerge as a prominent growth ground for the industry.

While massive data has been captured for advanced economies, dearth of data in African countries and most of the Gulf countries has signified the importance of precision medicine. Further, burgeoning population has also been one of the factors fueling growth in the region. MEA market was pegged at over USD 3.0 billion in 2019 and is estimated to expand at a CAGR of more than 10.0% during the forecast period.

View original post here:
Precision Medicine Market growth outlook with industry review and forecasts - GroundAlerts.com

object(stdClass)#31465 (59) { ["id"]=> string(4) "5792" ["title"]=> string(69) "How Blockchain Improves Logistics: Benefits, Drawbacks, and Use Cases" ["alias"]=> string(66) "how-blockchain-improves-logistics-benefits-drawbacks-and-use-cases" ["introtext"]=> string(177) "

The blockchain technology and logistics industry tend to be quite profitable for each other. Additionally, this collaboration brings benefits to carriers and customers.

In this article, well discuss all you need to know about blockchain in the logistics sector.

Blockchain allows optimizing logistic processes in the real-time mode. This technology tends to improve the relationship between shippers and carriers.

We've singled out six main advantages of using blockchain in the logistics sector. Lets discuss them more precisely.

There are a lot of documents required for the transportation process. For example, a bill of lading or B/L. It stands for an agreement that consists of transportation terms, conditions, and other issues.

Blockchain allows recording all the steps. As a result, any participant can look through the delivery chain. If something happens, recorded information will report a problem.

Blockchain allows optimizing routes and delivering faster. In this case, smaller companies can compete with bigger ones, offering faster routes.

As a result, its possible to reduce expenses on the shipping process.

Blockchain simplified the process of goods certification. The combination of IoT and blockchain allows creating smart contracts.

Transactions made on blockchain are secure. Its impossible to change something in the transaction. It leads to decreasing fraudulent operations.

Intermediaries stand for agents that take part in the transportation chain. However, withlogistics software development, the industry doesnt need such specialists.

Weve already mentioned smart contracts. They tend to reduce time and expenses. Also, both parties have an opportunity to automate the validation process, manage obligations, and so on.

There were main blockchain advantages. As you can see, this technology can be quite profitable for the logistics industry.

Of course, there are some disadvantages of using blockchain technology. Lets discuss them more precisely.

Blockchain allows automating supply processes. As a result, there is no need for various specialists. The number of unemployed workers will rise.

Businesses that use blockchain technology should have a standard process. Unfortunately, these days, businesses dont have one.

Its required to create a standard process on the government level. So, businesses can follow it to avoid some common problems.

Its evident that blockchain development is expensive and time-consuming. Additionally, its required to have powerful hardware.

Also, there are expenses on specialists that are experienced in blockchain integration.

So, blockchain is a quite expensive technology that requires additional preparation before using it. However, some companies have already integrated blockchain and got some profit.

Blockchain makes it easy to track goods during shipment. Additionally, the companies have an opportunity to monitor the conditions of the packages.

As a result, its possible to detect broken goods, spoilt products, and so on.

Of course, such opportunities lead to decreasing unnecessary expenditures.

Successful story. Walmart cooperates with IBM to use the blockchain technology in the logistics. The system allows seeing what products are sold. Also, its possible to know the location of the product (the particular warehouse). The company claims that the supply process becomes more transparent.

Blockchain allows reducing the number of documents required for transportation. Additionally, the number of mistakes will also decrease due to automatization. The shipping terms fulfill more precisely.

Let's face it payments are important for any business. Blockchain makes this process secure. For example, its possible to make transactions with such cryptocurrencies as Bitcoin. As a result, the payment process is secure and transparent. Also, such solutions improve international processes.

Successful story. Tallysticks has made a platform that simplified payment processes using blockchain. The solution offers smart contracts that can be customized depending on the business needs and requirements.

Blockchain gives end consumers an opportunity to simplify the authenticity of the goods. There are platforms with data about product origin, quality, fineness, and others.

This technology gives clients transparency. As a result, people trust companies more.

Blockchain makes cooperation easier. For example, enterprises can cooperate with small companies to deliver goods faster. Such a solution is profitable for both parties.

These days, companies can cooperate with each other without intermediaries. It leads to cost reduction and improved delivery processes.

Successful story. ShipChain platform uses blockchain to improve cooperation. For instance, the service allows tracking the delivery from the warehouse to the buyer's door. It leads to better customer experience and satisfaction.

The delivery process is long and expensive. Also, there can occur various delays due to weather conditions and other issues.

Usually, to manage such issues, companies hire lawyers. However, blockchain changes the situation. The transportation process is tracked from the beginning to the end. So, both parties can see any changes in the route.

Also, the parties can monitor any issues connected to the delivery and decide whose fault they were.

Blockchain technology innovates the logistics sector. The companies can simplify the delivery process, making routes shorter.

All these solutions lead to customer satisfaction. As a result, the clients trust companies and order goods or services more often.

The main advantage of blockchain is transparency. Business owners, as well as end consumers, have an opportunity to track the delivery process. Also, customers can ensure that during the delivery the storing conditions were followed.

However, developing blockchain-based solutions is an expensive and time-consuming process. Companies have to prepare beforehand and single out the requirements of the final product.

Link:
The Growing Role of Artificial Intelligence in the Pharmaceutical Industry - BBN Times

According to the latest study conducted by Trends Market Research (TMR) the global market for precision medicine is anticipate grow manifold, reflecting a robust CAGR of over XX% during 2018 to 2025.

Rapid augmentation of the medicine industry across the globe will certainly benefit the global market forprecision medicine. In addition, factors such as growing infrastructural development, higher investments, streamlined drug approval systems along with companion diagnostics are expected to favor the overall market growth during the assessment period. Cost-effective DNA profiling and increasing prevalence of carcinogenic diseases worldwide are additional factors that are projected to propel the market growth. Moreover, apt storage of genome data is of great significance to the global market for precision medicine as demand for data medicare is on the rise. However, acute data storage capacity, data privacy breach and discrepancies in funding systems and hefty price tag of personalized drugs may deter the market growth in the near future.

Enquiry More About This Report:https://www.trendsmarketresearch.com/report/sample/3437

The global market for precision medicine has been categorized into various parent segments that are further segmented into smaller sub-divisions.

On the basis of technology, next-gen sequencing, bioinformatics and drug discovery technology are expected to be the technologies highlighting the expanding the market width in forthcoming years. Based on applications, the oncology segment is expected to witness an overwhelming growth and is estimated to reach US$ XX Billion over 2025, reflecting a staggering XX% CAGR. This is primarily owing to increasing prevalence of tumor-related disease amongst the global geriatric population. On the other hand, increasing cases of arthritis will favor the growth of immunology segment, which is expected to surpass US$ XX Million in revenues by 2025 end.

Vendor News

Key players operating in the global market for precision medicine include Eli Lilly And Company, Novartis AG, AstraZeneca and Laboratory Corporation of America Holdings. Most of the companies are implementing market strategies involving mergers, tie-ups and acquisitions. Increasing collaboration between healthcare and IT is expected to deliver fruitful gains to the market, expanding the overall business canvas for the stakeholders in the upcoming years.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/3437

The popularity of precision medicine has grown significantly across various parts of the world, hence on the basis of region, the markets for precision medicine in Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa (MEA) is set to achieve new figures of growth over the next eight years. Precisely, the market in North America is expected to present new lucrative opportunities, occupying over XX% share of the market during the forecast period. In addition, the region is estimated to surpass a market valuation of over US$ XX Million by the end of 2025.

The US and Canada will be the heavyweights of the global market owing to the existence of well-established medical industries in both the countries. In Europe, the market is expected to witness a steady growth and will increase its revenues charts close to US$ XX Million, riding on a healthy CAGR of over XX% during the assessment period. This is largely due to the increasing demand for precision medicines in countries such as France, UK, Italy and Germany. The Asia Pacific region is another region which is considered to be full of business potentials. The region is projected to increase at over XX% CAGR to reach approximately US$ XX Million by 2025 end. The market in APAC will be heavily dominated by Japan, while, India and China will compete for the second spot. Likewise, the in Latin America the market is expected to surge at a pace in terms of revenue over 2025. However, MEA will witness a sluggish growth of the market which is attributed to the lack of initiatives for conductive extensive research and development activities.

Make an Inquiry before [emailprotected] https://www.trendsmarketresearch.com/checkout/3437/Single

Visit link:
Precision Medicine Market to Witness a Healthy Growth during 2018-2025 - Curious Desk

Florida sees increased coronavirus tests and a surge in cases

The latest numbers show the state has tested about nine times more people for coronavirus than it did just a week ago. At the same time, the number of positive cases has surged. It makes sense that if you test more, youll find more coronavirus. But thats only a partial explanation for the swift rise in Covid-19 cases. USF Public Health Professor Jay Wolfson says the lack of testing up until now means that people who didnt know they were infected could have given the virus in a worst case -- to a thousand people in a week. [Source: Health News Florida]

Florida to allow recently retired health care workers to return to work

Gov. Ron DeSantis said Monday that he plans to sign an executive order allowing recently retired law enforcement and health care professionals to return to the workforce to help fight coronavirus. We need to have folks that are willing to return to service, DeSantis said. DeSantis said his order will allow recently retired law enforcement and health care personnel to return to work immediately. [Source: WESH]

Hotels could be used for medical surge

Health care facilities are preparing for the worst-case scenario: a medical surge that could overwhelm bed space inside hospitals. Some facilities are looking into other buildings and spaces that could be used to care for a large wave of COVID-19 patients. Dr. Stanley Marks, chief medical officer at Memorial Healthcare System in Broward County, talks about COVID-19 preparation efforts. [Source: WLRN]

Southwest Florida medical practice digests large growth plans

Lakewood Ranch physician Dr. Arun Khazanchi takes the future of the medical practice he leads, Florida Digestive Health Specialists, personally. As in personalized medicine. Like many physicians and health care providers, Khazanchi can see medicine is moving fast toward a world where biomarkers, genetic research and tailored treatments dominate health care no matter the payment system. [Source: Business Observer]

DeSantis orders Attorney General to investigate South Florida hospital

Florida Gov. Ron DeSantis called on the state attorney general Friday to investigate a South Florida hospital charging $150 per test for COVID-19, the disease caused by the novel coronavirus spreading rapidly across the state. While DeSantis did not name the hospital, Larkin Community Hospital operates a drive-thru testing site in Hialeah and charges $150 per test. [Source: WUSF]

ALSO AROUND FLORIDA:

What is a child health advocate in Florida? [NBC-2]From Gun safety to ATV safety, even sleep safety, child advocates at Golisano Childrens Hospital of Southwest Florida are focused on keeping children out of the hospital. A child advocate is somebody thats passionate about keeping kids safe in the community, whether that means one-on-one with the family, or one-on-one with kids, grandparents, said Sally Kreuscher, child advocacy program coordinator with Golisano Childrens Hospital.

Medical cannabis access an essential service sort of [The Lakeland Ledger]With nearly 328,000 Floridians officially registered as medical marijuana patients, the coronavirus has forced the states hand into declaring cannabis an essential component of health care. Unless, of course, youre a new patient in need of a card. In that case, you may be out of luck, for at least through the middle of next month.

Sarasota quilters sew face masks for health care workers [Sarasota Herald-Tribune]As the coronavirus pandemic mounts in the U.S. each day, the nation is facing a shortage of face masks for health care workers. The South Sarasota Modern Quilt Guild, like other sewing groups across the country, tapped into their talent to work on a solution. The guilds members have been busy at work for the past week sewing cotton face masks for health care professionals to wear on top of their disposable N95 masks.

Hillsborough among areas receiving hydroxychloroquine [WUSF]Hillsborough County is among the areas in Florida being hardest hit with coronavirus that will receive a shipment of hydroxychloroquine, a drug that is being touted by some as a possible treatment for the symptoms of coronavirus. During a news conference on Saturday, Gov. Ron DeSantis said he worked with David Friedman, the U.S. ambassador to Israel who he said he considers a friend -- to arrange the shipment from Israeli company Teva Pharmaceuticals.

Tags:Health Care eNews

Previous Health Care Updates:

View post:
Florida sees increased coronavirus tests and a surge in cases - Florida Trend

WASHINGTON: Researchers have created artificial proteins that can control the activity of genes and other molecules in living cells in predetermined ways, an advance that can be used to program the behaviour of more complex chemical and biological systems.

In the study, published in the journal Science, the scientists showed that the designer proteins can regulate the activity of genes inside the human immune system's T-cells, adding that the development may improve the safety and durability of future cell-based therapies.

The researchers, including those from the University of Washington in the US, explained that the proteins, like their electronic counterparts, logic gates, implement a Boolean function, which is a logical operation performed on one or more binary inputs that produces a single binary output.

They explained that these logic gates sense and respond to signals in predetermined ways.

Citing an example, the scientists said, the 'AND' gate produces output only when one input AND another are present.

When typing on a keyboard, pressing the Shift key AND the A key produces an uppercase letter A, they explained.

The novel protein logic gates, made from biological parts, aim to bring this level of control into bioengineered systems, the researchers added.

"Bioengineers have made logic gates out of DNA, RNA and modified natural proteins before, but these are far from ideal. Our logic gates built from de novo designed proteins are more modular and versatile, and can be used in a wide range of biomedical applications" said study senior author David Baker from the University of Washington.

Using proteins like the one currently developed, the scientists said, inputs such as the presence of two different molecules in a living cell can cause it to produce a specific output, such as activating or suppressing a gene.

"The whole Apollo 11 Guidance Computer was built from electronic NOR gates," said lead author Zibo Chen, a recent UW graduate student.

"We succeeded in making protein-based NOR gates. They are not as complicated as NASA's guidance computers, but nevertheless are a key step toward programming complex biological circuits from scratch," Chen added.

While recruiting a patient's own immune cells in the fight against cancer has worked for certain forms of the disease, targeting solid tumours with genetically engineered T-cells has proven challenging.

Based on earlier studies, the researchers believe this could in-part be due to T cell exhaustion.

Genetically altered T cells can fight for only so long before they stop working, they explained.

But with protein logic gates that respond to exhaustion signals, the scientists hope to prolong the activity of genetically modified T cells.

"Longer-lived T cells that are better programmed for each patient would mean more effective personalized medicine," Chen said.

Read the original:
Researchers develop novel 'smart' proteins programmed to turn genes on and off - Economic Times

TOKYO--(BUSINESS WIRE)--CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device Digital Therapeutics mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.

This study will evaluate the efficacy and safety of "Digital Therapeutics" in patients with essential hypertension who have not received an orally administered antihypertensive drug treatment. Patients will be divided into two groups; those using "Digital Therapeutics" in addition to lifestyle changes set according to the Guidelines for the Management of Hypertension 2019 (the "Guidelines) (*1), and those only adopting said lifestyle habit changes without using Digital Therapeutics. The primary criteria for evaluation is the change from the baseline in mean 24-hour systolic blood pressure*1 at 12 weeks after treatment begins, as measured by ambulatory blood pressure monitoring (ABPM)*2.

*1 Systolic blood pressure: Highest blood pressure in blood pressure measurement*2 Ambulatory blood pressure monitoring: Continuous measurement of blood pressure at certain intervals for 24 hours under normal lifestyle conditions. Blood pressure fluctuates due to various factors; this shows the daily variation in blood pressure (daily variation pattern).

Hypertension is the biggest risk factor for cerebrovascular and cardiovascular diseases (i.e. stroke, heart disease), and the annual death toll in Japan from these diseases attributed to hypertension is estimated to reach 100,000. The number of patients with hypertension in Japan is estimated approx. 43 million, and blood pressure is appropriately controlled in only 12 million of these patients (*1). The lifestyle improvements essential to hypertension treatment are difficult to sustain as they are largely dependent on a patients motivation or their workplace/home environment. At the same time, successful lifestyle intervention by medical institutions presents a challenge.

Under these circumstances, "Digital Therapeutics," a new treatment method utilizing mobile technology, aims to produce a strong therapeutic effect enabling patients to return to normal blood pressure and develop appropriate lifestyle habits by providing personalized, optimized treatment guidance to individual patients based on medical evidence and encouraging awareness/behavior changes. The hypertension treatment application used in this study will automatically analyze blood pressure and lifestyle characteristics of individuals from data that includes blood-pressure monitoring using a smart blood pressure monitor and lifestyle habit logs. This data will be used to provide optimal treatment guidance (advice on diet, exercise, sleep, etc., and information to encourage behavior improvements).

[Source](*1): The Guidelines for the Management of Hypertension 2019 [JSH2019], The Japanese Society of Hypertension (2019) https://www.jpnsh.jp/guideline.html

Professor Kazuomi Kario, M.D., Ph.D.Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine

Hypertension is the biggest risk factor for serious cardiovascular diseases such as stroke, myocardial infarction, and cardiac failure. Although thoroughgoing antihypertensive measures ensures to control these diseases, the control rate for hypertension in Japan is only about 30% at present. Reducing salt and alcohol intake, proper weight control, and exercise are very important in treating hypertension. However, these measures are difficult to maintain on a continual basis. Digital Therapeutics is the worlds first app to treat hypertension that provides full support for improving lifestyle habits directly lowering blood pressure by encouraging behavioral changes based on cognitive behavioral therapy. With its elaborate treatment program and the innovative application of new information technology, Digital Therapeutics assesses individual patients, and ensures an interactive information exchange between patients and physicians based on appropriate guidance with proven scientific evidence and patient behavior records. I hope to see this app serving as the first step toward realizing a self-cure of hypertension by closely monitoring the daily lives of individuals to help them improve their lifestyle habits.

Kohta Satake, M.D.President and CEO, CureApp, Inc.

The spread of Hypertension Digital Therapeutics as a treatment covered by health insurance will lead to preventing the progression of hypertension and inhibiting cardiovascular diseases. After this clinical trial, we aim to obtain regulatory approval and health insurance coverage. "Digital Therapeutics" can provide appropriate medical guidance to patients at home and outside the hospital, making it possible to provide high-quality personalized medical care to people of working age who find it difficult to make frequent visits to clinics, as well as people in remote areas. I feel certain that the increased use of "Digital Therapeutics," a new therapeutic approach using digital technology, will create new value in medical care for hypertension and contribute to reducing future medical costs.

About CureApp, Inc.

CureApp, Inc. is a MedTech start-up company that performs research and development and produces software as a medical device for disease treatments based on advanced software technology and medical evidence. CureApp pursues the research and development of "Digital Therapeutics, a disease treatment app, to establish a new form of medical service in Japan with a concept of an app that cures diseases.

"Digital Therapeutics" draws on a daily therapeutic process tailored to each patient to provide new therapeutic effects through analysis and guidance based on medical knowledge and evidence. Encouraging patients to improve their habits through raising their awareness and changing their behavior may also contribute to disease improvement. We clearly differentiate "Digital Therapeutics" app from the other unapproved healthcare applications as we aim to demonstrate the therapeutic effect of the "Digital Therapeutics" app in clinical studies, etc., obtain regulatory approval, and commercialize them as medical devices in the future. CureApp led the way in launching clinical studies of therapeutic application in Japan, and our first therapeutic application, Therapeutic Application for Nicotine Addiction," has completed clinical trials and is currently under application for regulatory approval. Development and clinical research on therapeutic applications for hypertension and NASH (non-alcoholic steatohepatitis) have also launched. We plan to leverage our U.S. subsidiary, which we founded last year, serve as a base of operations for broadly rolling out such "digital health solutions from Japan based on the model developed in Japan.

At present, the development status of "Digital Therapeutics" is as follows.

"Digital Therapeutics" is the registered trademark of CureApp, Inc.

General information of Jichi Medical UniversityName: Jichi Medical UniversityLocation: 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken, JapanRepresentative: Toshio Oishi, Chairman of the BoardEstablished: February 1972URL: https://www.jichi.ac.jp/english/index.html

Corporate Profile of CureApp, Inc.Company Name: CureApp, Inc.President and CEO: Kohta Satake, M.D.Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, JapanEstablished: July 31, 2014Business Description: Development of programmed medical devices, health-related mobile servicesURL: https://cureapp.co.jp/en/

See the original post:
Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan -...

DUBLIN, April 6, 2020 /PRNewswire/ -- The "Gut-on-a-Chip Market" report has been added to ResearchAndMarkets.com's offering.

The scope of this report is broad and covers various types of products available in the gut-on-a-chip market and the market's major geographical regions. Regions include North America, Europe, Asia-Pacific, and Rest of the World. The market size is estimated using data triangulation with both top-down and bottom-up approaches.

The market size was estimated by deriving the revenues of manufacturers. Revenue generated from the installation and maintenance of instruments has been excluded from this report.

This report explains the regional dynamics of the global market and regulatory scenario within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major players in the global gut-on-a-chip market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Analysis

Chapter 5 Market Breakdown by Application

Chapter 6 Market Breakdown by Region

Chapter 7 Regulatory Environment

Chapter 8 Competitive Landscape

Chapter 9 Company Profiles

Chapter 10 Recommendations and Conclusions

List of TablesSummary Table: Global Gut-on-a-Chip Market, by Region, 2018Table 1: Design Characteristics of Microfluidic Intestine ModelsTable 2: Global Gut-on-a-Chip Market, 2017 and 2018Table 3: Global Gut-on-a-Chip Market, by Application, 2018Table 4: Global Gut-on-a-Chip Market, by Region, 2018Table 5: Company Rankings in the Global Gut-on-a-Chip MarketTable 6: Beonchip: Product PortfolioTable 7: Beonchip: Recent Developments, 2018Table 8: Emulate Inc.: Product PortfolioTable 9: Emulate Inc.: Recent Developments, 2017-2019Table 10: Mimetas B.V.: Product PortfolioTable 11: Mimetas B.V.: Recent Developments, 2017-2019Table 12: TissUse GmbH: Product PortfolioTable 13: TissUse GmbH: Recent Developments, 2018 and 2019

List of FiguresSummary Figure: Global Gut-on-a-Chip Market Shares, by Region, 2018Figure 1: Global Organ-on-a-Chip Market Shares, 2018Figure 2: Global Gut-on-a-Chip Market Shares, by Application, 2018Figure 3: Global Gut-on-a-Chip Market Shares, by Region, 2018

For more information about this report visit https://www.researchandmarkets.com/r/ptwa46

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
2020 Gut-on-a-Chip Industry Insights by Application & Region, Featuring Profiles of Beonchip, Emulate, Mimetas and Tissuse - PRNewswire

DUBLIN, March 20, 2020 /PRNewswire/ -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of Delivery), End User (Healthcare Providers, Healthcare Payers, Government Bodies)] - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global population health management market is projected to reach USD 39.4 billion by 2025 from USD 22.9 billion in 2020, at a CAGR of 11.5% during the forecast period.

Government mandates and support for healthcare IT solutions, increasing use of big data analytics, and the need to curtail the escalating healthcare costs are the key factors driving the growth of the population health management market. In addition, emerging economies (such as Brazil, Russia, India, South Korea, and China), increasing focus on personalized medicine, and rising focus on value-based medicine are expected to offer lucrative growth opportunities for market players during the forecast period. However, data breaches, lack of skilled analysts, and interoperability issues are adversely impacting the growth of this market.

The software segment accounted for the larger share of the population health management market, by component, in 2019

On the basis of component, the population health management market is segmented into software and services. The software segment accounted for the largest share of the population health management market in 2019. Technological advancements in IT solutions and big data analytics, growth of cloud computing, and increasing penetration of the Internet across the globe are some of the key factors driving the demand for software-based HCIT solutions. Moreover, the adoption of population health management software to coordinate care processes is expected to increase in the coming years owing to its ability to reduce readmissions, increase cost-effectiveness, and enhance patient engagement.

By mode of delivery, the on-premise mode of delivery segment accounted for the largest market share in 2019

Population health management solutions are delivered to end users through the on-premise and cloud-based modes of delivery. The on-premise solutions segment accounted for the larger market share in 2019. The advantages offered by the on-premise mode of delivery, and the ability to reuse existing servers and storage hardware are supporting its increased adoption in the population health management market.

By end user, the healthcare providers segment accounted for the largest market share in 2019

On the basis of end user, the population health management market is segmented into healthcare providers, healthcare payers, and other end users. In 2019, the healthcare providers segment accounted for the largest share of the population health management market. The advantages offered by PHM solutions, growing pool of patients, increasing load on hospitals to integrate and manage patient data in a more efficient way, and the growing need to improve the affordability and accessibility of healthcare services are propelling the growth of the PHM solutions market for healthcare providers.

APAC is the fastest-growing market for population health management.

The population health management market in the APAC is expected to witness the highest CAGR during the forecast period. The growth of the Asia Pacific population health management market is driven by the rising medical tourism, the implementation of new ICT guidelines in Japan, investments and reforms to modernize China's healthcare infrastructure, the rapidly growing healthcare industry in India, and the implementation of IT programs in Australia and New Zealand. In addition, government initiatives for the adoption of HCIT, the growing geriatric population, rising prevalence of chronic diseases, increasing healthcare expenditure, and the rising purchasing power of consumers are also expected to support market growth in this region.

Story continues

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Market Overview4.2 North America: Market, By Component & Country (2019)4.3 Population Health Management Market: Geographic Growth Opportunities

5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Mandates & Support for Healthcare IT Solutions5.2.1.2 Increasing Use of Big Data Analytics5.2.1.3 Need to Curtail Escalating Healthcare Costs5.2.2 Restraints5.2.2.1 Huge Investments in Infrastructure to Set Up A Robust PHM Program5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Rising Focus on Personalized Medicine5.2.3.3 Increasing Focus on Value-Based Medicine5.2.4 Challenges5.2.4.1 Data Breaches5.2.4.2 Lack of Data Management Capabilities and Skilled Analysts5.2.4.3 Interoperability Issues

6 Population Health Management Market, By Component 6.1 Introduction6.2 Software6.2.1 Software is the Largest Component Segment of the Market6.3 Services6.3.1 Increasing Adoption of PHM Solutions & Indispensable & Recurring Nature of Services to Drive Market Growth

7 Population Health Management Market, By Mode of Delivery 7.1 Introduction7.2 On-Premise Mode of Delivery7.2.1 On-Premise Mode of Delivery Segment Accounted for the Largest Market Share in 20197.3 Cloud-Based Mode of Delivery7.3.1 Cloud-Based Mode of Delivery Segment to Register the Highest Growth in the PHM Market Between 2020 & 2025

8 Population Health Management Market, By End User 8.1 Introduction8.2 Healthcare Providers8.2.1 Growing Need to Improve the Profitability of Healthcare Operations is Driving the Use of PHM Solutions Among These End Users8.3 Healthcare Payers8.3.1 Increased Focus on Outcome-Based Payment Models has Driven the Demand for PHM Solutions Among Healthcare Payers8.4 Other End Users

9 Population Health Management Market, By Region 9.1 Introduction9.2 North America9.2.1 US9.2.1.1 The US is the Largest Market for Population Health Management Solutions9.2.2 Canada9.2.2.1 Deployment of Digital Health Initiatives is Boosting Market Growth in Canada9.3 Europe9.3.1 Germany9.3.1.1 Germany Dominates the European Population Health Management Market9.3.2 UK9.3.2.1 Increasing Public-Private Initiatives to Support the Adoption of PHM Solutions in the Country9.3.3 France9.3.3.1 Rising Geriatric Population and the Increasing Patient Volume for Various Chronic and Age-Related Conditions to Drive Market Growth9.3.4 Italy9.3.4.1 Government Initiatives to Support Market Growth in Italy9.3.5 Spain9.3.5.1 Increasing Adoption of PHM Solutions to Support Market Growth in Spain9.3.6 Rest of Europe9.4 Asia Pacific9.4.1 Japan9.4.1.1 Japan Accounted for the Largest Share of the APAC PHM Market in 20199.4.2 China9.4.2.1 Strong Government Support in China is Driving the PHM Market9.4.3 India9.4.3.1 Growing Volume of Patient Data Generated Within Healthcare Systems to Propel the Market for PHM Solutions in India9.4.4 Rest of Asia Pacific (RoAPAC)9.5 Rest of the World9.5.1 Latin America9.5.1.1 Brazil, Argentina, and Mexico are Emerging Healthcare Markets in Latin America9.5.2 Middle East & Africa9.5.2.1 Increasing Investments in Modernizing Healthcare Systems are Propelling Market Growth

10 Competitive Landscape 10.1 Introduction10.2 Competitive Leadership Mapping (Overall Market)10.2.1 Visionary Leaders10.2.2 Innovators10.2.3 Dynamic Differentiators10.2.4 Emerging Companies10.3 Competitive Scenario

11 Company Profiles 11.1 Cerner Corporation11.2 Epic Systems Corporation11.3 Koninklijke Philips11.4 I2I Population Health11.5 Health Catalyst11.6 Optum (Part of Unitedhealth Group)11.7 Enli Health Intelligence11.8 Eclinicalworks11.9 Allscripts Healthcare Solutions11.1 IBM Corporation11.11 Healthec, LLC11.12 Medecision11.13 Arcadia11.14 Athenahealth11.15 Cotiviti (Verscend Technologies)11.16 Nextgen Healthcare Inc.11.17 Conifer Health Solutions11.18 SPH Analytics11.19 Lightbeam Health Solutions11.20 Innovaccer

For more information about this report visit https://www.researchandmarkets.com/r/q02un0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/population-health-management-industry-forecast-to-2025-a-39-billion-landscape-opportunity-301027444.html

SOURCE Research and Markets

See more here:
Population Health Management Industry, Forecast to 2025: A $39+ Billion Landscape Opportunity - Yahoo Finance

Verified Market Research recently published a research report titled, Personalized Medicine Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Personalized Medicine market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=BCC&utm_medium=002

Personalized Medicine Market Leading Players:

Personalized Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Personalized Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Personalized Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Personalized Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Personalized Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Personalized Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Personalized Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Forecast, Personalized Medicine Market Growth, Personalized Medicine Market Analysis

Read more from the original source:
Personalized Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - NJ MMA News

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients.

The study analyzed more than 1,000 pancreatic cancer patients enrolled in PanCAN's Know Your Tumor precision medicine service, powered by Perthera, and found those patients who received matched therapies following molecular profiling of their tumor, using the Perthera Platform, saw an overall survival benefit of one year longer than those who did not.

Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 10 percent. It is currently the third leading cause of cancer-related death in the U.S., underscoring the urgent need for new treatment options and research discoveries in this space.

When PanCAN's Know Your Tumor service was started with Perthera in 2014, key precision medicine resources such as molecular profiling were rarely offered to patients with pancreatic cancer because many doctors assumed there wasn't anything actionable to be found. The study showed that approximately 25 percent of pancreatic cancer patients have an actionable alteration. It also underscores the significance of the most recent National Comprehensive Cancer Network (NCCN) guidelines that state that every patient with pancreatic cancer should get testing - both molecular profiling of their tumor and germline (genetic) testing for alterations they were born with.

The results of this study will help re-write the future for cancer patients for years to come, said Gary Gregory, CEO & President, Perthera, Inc. Increasing patient survival is the cornerstone of the work that PanCAN has spearheaded with Perthera across the U.S. This study clearly proves that, by utilizing precisely matched therapies provided by molecular profiling, along with Therapeutic Intelligence and a Molecular Tumor Board, patients with pancreatic cancer have experienced significant increases in both overall and progression-free survival.

This is critical news for pancreatic cancer patients. Every tumor is different and through this study, we know that patients who get tested and receive treatment based on their tumor's biological characteristics are living longer, said Lynn Matrisian, PhD, MBA, Chief Science Officer at PanCAN and an author on the paper. It is a strong reminder to healthcare professionals to offer tumor profiling to all their pancreatic cancer patients. And it will further provide an incentive to the scientific community to pursue new targeted treatments for even more pancreatic cancer patients.

Several of the molecularly-matched therapies given have now been FDA approved for patients with pancreatic cancer based on select biomarkers. Adopting molecular profiling into routine practice will be critically important to making sure these patients do not miss out on life-extending opportunities that can now be covered by insurance. These real-world outcomes suggest that the adoption of a precision medicine platform can have a substantial impact on survival in patients with pancreatic cancer, and that molecularly-guided treatments targeting oncogenic drivers and the DNA damage repair pathway warrant further prospective evaluation, said Mike Pishvaian, MD, PhD, Perthera's Chief Medical Officer GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Johns Hopkins Medicine.

PanCAN recommends that all pancreatic cancer patients undergo testing of both their tumor tissue (molecular profiling) and blood or saliva for genetic (germline) changes to determine if they have an actionable alteration and to identify treatment options for that patient. Patients can enroll in PanCAN's free Know Your Tumor precision medicine service today, as well as receive free, in-depth, and personalized resources and information on the disease through PanCAN's Patient Central.

The Perthera Platform has been proven to capitalize upon actionable alterations and improve patient outcomes across numerous, peer reviewed clinical publications. The Perthera Platform, which has been used by over 250 cancer treatment sites across the U.S., captures a patient's entire medical and treatment history, as well as their multi-omic molecular profile, to create a personalized treatment plan, that enable physicians to effectively harness the power of precision medicine.

More here:
New Research Reveals Pancreatic Cancer Patients Who Receive Precision Medicine Live An Average Of One Year Longer Than Those Who Do Not #47579 - New...

Artificial Intelligence (AI) is getting increasingly sophisticated day by day in its application, with enhanced efficiency and speed at a lower cost. Every single sector has been reaping benefits from AI in recent times. The Healthcare industry is no exception. Here is decoding the future trajectory of healthcare with AI.

The impact of artificial intelligence in the healthcare industry through machine learning (ML) and natural language processing (NLP) is transforming care delivery. Additionally, patients are expected to gain relatively high access to their health-related information than before through various applications such as smart wearable devices and mobile electronic medical records (EMR).

The personalized healthcare will authorize patients to take the wheel of their well-being, facilitate high-end healthcare, and promote better patient-provider communication to underprivileged areas.

For instance, IBM Watson for Health is helping healthcare organizations to apply cognitive technology to provide a vast amount of power diagnosis and health-related information.

In addition, Googles DeepMind Health is collaborating with researchers, clinicians, and patients in order to solve real-world healthcare problems. Additionally, the company has combined systems neuroscience with machine learning to develop strong general-purpose learning algorithms within neural networks to mimic the human brain.

Companies are working towards developing AI technology to solve several existing challenges, especially within the healthcare space. Strong focus on funding and starting AI healthcare programs played a significant role in Microsoft Corporations decision to launch a 5-year, US$ 40 million program known as AI for Health in January 2019.

The Microsoft program will use artificial intelligence tools to resolve some of the greatest healthcare challenges including global health crises, treatment, and disease diagnosis. Microsoft has also ensured that academia, non-profit, and research organizations have access to this technology, technical experts, and resources to leverage AI for care delivery and research.

In January 2020, these factors influenced Takeda Pharmaceuticals Company and MITs School of Engineering to join hands for three years to drive innovation and application of AI in the healthcare industry and drug development.

AI applications are only centered on three main investment areas: Diagnostics, Engagement, and Digitization. With the rapid advancement in technologies. There are exciting breakthroughs in incorporating AI in medical services.

The most interesting aspect of AI is robots. Robots are not only replacing trained medical staff but also making them more efficient in several areas. Robots help in controlling the cost while potentially providing better care and performing accurate surgery in limited space.

China and the U.S. have started investing in the development of robots to support doctors. In November 2017, a robot in China passed a medical licensing exam using only an AI brain. Also, it was the first-ever semi-automated operating robot that was used to suture blood vessels as fine as 0.03 mm.

In order to prevent coronavirus from spreading, the American doctors are relying on a robot that can measure the patients act and vitals. In addition, robots are also being used for recovery and consulting assistance and transporting units. These robots are showcasing significant potential in revolutionizing medical procedures in the future.

Precision medicine is an emerging approach to disease prevention and treatment. The precision medication approach allows researchers and doctors to predict more accurate treatment and prevention strategies.

The advent of precision medicine technology has allowed healthcare to actively track patients physiology in real-time, take multi-dimensional data, and create predictive algorithms that use collective learnings to calculate individual outcomes.

In recent years, there has been an immense focus on enabling direct-to-consumer genomics. Now, companies are aiming to create patient-centric products within digitization processes and genomics related to ordering complex testing in clinics.

In January 2020, ixLayer, a start-up based in San-Francisco, launched one of its kind precision health testing platforms to enhance the delivery of diagnostic testing and to shorten the complex relationship among physicians, precision health tests, and patients.

Personal health monitoring is a promising example of AI in healthcare. With the emergence of advanced AI and Internet of Medical Things (IoMT), demand for consumer-oriented products such as smart wearables for monitoring well-being is growing significantly.

Owing to the rapid proliferation of smart wearables and mobile apps, enterprises are introducing varied options to monitor personal health.

In October 2019, Gali Health, a health technology company, introduced its Gali AI-powered personal health assistant for people suffering from inflammatory bowel diseases (IBD). It offers health tracking and analytical tools, medically-vetted educational resources, and emotional support to the IBD community.

Similarly, start-ups are also coming forward with innovative devices integrated with state-of-the-art AI technology to contribute to the growing demand for personal health monitoring.

In recent years, AI has been used in numerous ways to support the medical imaging of all kinds. At present, the biggest use for AI is to assist in the analysis of images and perform single narrow recognition tasks.

In the United States, AI is considered highly valuable in enhancing business operations and patients care. It has the greatest impact on patient care by improving the accuracy of clinical outcomes and medical diagnosis.

Strong presence of leading market players in the country is bolstering the demand for medical imaging in hospitals and research centers.

In January 2020, Hitachi Healthcare Americas announced to start a new dedicated R&D center in North America. Medical imaging will leverage the advancements in machine learning and artificial intelligence to bring about next-gen of medical imaging technology.

With a plethora of issues driven by the growing rate of chronic disease and the aging population, the need for new innovative solutions in the healthcare industry is moving on an upswing.

Unleashing AIs complete potential in the healthcare industry is not an easy task. Both healthcare providers and AI developers together will have to tackle all the obstacles on the path towards the integration of new technologies.

Clearing all the hurdles will need a compounding of technological refinement and shifting mindsets. As AI trend become more deep-rooted, it is giving rise to highly ubiquitous discussions. Will AI replace the doctors and medical professionals, especially radiologists and physicians? The answer to this is, it will increase the efficiency of the medical professionals.

Initiatives by IBM Watson and Googles DeepMind will soon unlock the critical answers. However, AI aims to mimic the human brain in healthcare, human judgment, and intuitions that cannot be substituted.

Even though AI is augmenting in existing capabilities of the industry, it is unlikely to fully replace human intervention. AI skilled forces will swap only those who dont want to embrace technology.

Healthcare is a dynamic industry with significant opportunities. However, uncertainty, cost concerns, and complexity are making it an unnerving one.

The best opportunity for healthcare in the near future are hybrid models, where clinicians and physicians will be supported for treatment planning, diagnosis, and identifying risk factors. Also, with an increase in the number of geriatric population and the rise of health-related concerns across the globe, the overall burden of disease management has augmented.

Patients are also expecting better treatment and care. Due to growing innovations in the healthcare industry with respect to improved diagnosis and treatment, AI has gained consideration among the patients and doctors.

In order to develop better medical technology, entrepreneurs, healthcare service providers, investors, policy developers, and patients are coming together.

These factors are set to exhibit a brighter future of AI in the healthcare industry. It is extremely likely that there will be widespread use and massive advancements of AI integrated technology in the next few years. Moreover, healthcare providers are expected to invest in adequate IT infrastructure solutions and data centers to support new technological development.

Healthcare companies should continually integrate new technologies to build strong value and to keep the patients attention.

-

The insights presented in the article are based on a recent research study on Global Artificial Intelligence In Healthcare Market by Future Market Insights.

Abhishek Budholiya is a tech blogger, digital marketing pro, and has contributed to numerous tech magazines. Currently, as a technology and digital branding consultant, he offers his analysis on the tech market research landscape. His forte is analysing the commercial viability of a new breakthrough, a trait you can see in his writing. When he is not ruminating about the tech world, he can be found playing table tennis or hanging out with his friends.

See the original post:
Decoding the Future Trajectory of Healthcare with AI - ReadWrite

Report Scope: The report provides a comprehensive summary of cloud computing for cell biology, genomics and drug design along with detailed profiles of key market players including a revenue product portfolio and recent activities.

New York, March 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cloud Computing in Cell Biology, Genomics and Drug Development" - https://www.reportlinker.com/p05873501/?utm_source=GNW The report analyzes trends and dynamics including drivers, limitations, challenges and opportunities.

The report discusses strategies adopted by emerging market players with recommendations for new market entrants.This research study discusses historical, current and potential market size.

The report will help market players and new entrants to make informed decisions about the production and export of goods and services, as well as providing organizations, distributors and exporters information about market development and trends.The study segments the market on the basis of applications and end uses.

A geographical market analysis is provided for all major segments.

Report Includes: - 43 data tables and 18 additional tables - An overview of the global market for cloud computing applications in cell biology, genomics and drug development - Analyses of global and regional market trends, with data from 2018 to 2019, and projections of compound annual growth rates (CAGRs) through 2024 - Assessment of market trends and opportunities, key developments and the impact of cloud computing technology on the biotechnology, pharmaceutical and healthcare industry verticals - Insight into recent developments in cloud infrastructure and information pertaining to key partnerships between cloud service providers and pharma/biotech companies and investment in pharmaceutical R&D sector - Discussion of the suppliers landscape, as well as the market positioning and strategies of key manufacturers and suppliers for cloud computing applications - Review of patent applications filed regarding cloud computing technology in the U.S. healthcare sector - Company profiles of the leading market players, including Amazon Web Services (AWS) Inc., Cisco Systems Inc., DXC Technology, Google LLC, Salesforce.com Inc., and SAP SE

Summary The global market for cloud computing in cell biology, genomics and drug development is estimated to grow at a CAGR of REDACTED during the forecast period.The market was valued at REDACTED in 2018 and is expected to reach REDACTED in 2024.

In biomedical research, cloud computing has resolved big data concerns and improves data, analytics, collaboration and sharing. Increasing biomedical research based on human, animal, plants, and microbes has increased the dependency on proper storage and network infrastructure as well as secure and scalable computing.

With growing big data concerns, researchers are inclined towards cloud computing platforms.These platforms provide flexibility to users to pay according to their usage of cloud services including software, hardware infrastructure and platforms to solve biomedical computation concerns.

The cloud offers ondemand storage and an analysis facility to users which makes it an emerging computing platform to address big data concerns.Owing to the flexibility and cost-effectiveness, cloud services are gaining significant importance in life science research for data storage, communication and collaboration with stakeholders.

On cloud platforms, large datasets and applications for gene sequencing, image analysis, protein folding and data mining can be shared for collaborative research between facilities.

The major pivotal factors contributing to the growth of the market include rising genomics and proteomics research and the increasing number of clinical trials performed across various countries.Considerable public and private investment in genomics and proteomics research is providing support to biotechnology start-ups and research institutes.

This helps healthcare providers to develop and commercialize genomics technologies and personalized medicines. Increasing U.S. FDA approvals for personalized medicines are supporting the growth in genomics research. For example, according to the Personalized Medicine Coalition, in 2018, approximately REDACTED of the REDACTED new molecular entities (NMEs) approved by the FDA are personalized medicines which constitute REDACTED of all new drug approvals. The Coalition classified REDACTED of NMEs as personalized medicines in 2017, REDACTED in 2015 and REDACTED in 2016. The U.S. FDA is making efforts to facilitate access to genomic testing and integration of real-world evidence into its regulatory framework. As a result, the FDA has begun to authorize the marketing of cancer-related genetic tests, and pharmacogenetics were allowed to be sold directly to the consumers. This has resulted in the development of personalized medicine as an emerging practice of medicine that utilizes the genetic profile of an individual to make appropriate decisions regarding prevention, diagnosis and treatment of the condition. Gaining complete knowledge about the patients genetic profile helps doctors to choose proper therapy or medication and to administer it with the proper regimen or dose. Significant data is generated by sequencing a single human genome which necessitates the adoption of cloud services. The 1000 Genomes Project is an effort to sequence genomes of at least a thousand people from across the globe to develop the most comprehensive and medically relevant picture of human genetic variation. This initiative intends to make genomic data easily accessible from international research institutions. Major support for the project is offered by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), Wellcome Trust Sanger Institute in Hinxton, England and the Beijing Genomics Institute, Shenzhen (BGI Shenzhen) in China.Read the full report: https://www.reportlinker.com/p05873501/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Original post:
Cloud Computing in Cell Biology, Genomics and Drug Development - Yahoo Finance

With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development

MINNEAPOLIS, March 12, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (POAI) (POAI or the Company), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announces it will launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS) through an operating agreement with Soluble Therapeutics. POAI has also signed a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its assets and its HSCTM Technology.

Global health experts are predicting an ever-increasing number of viral outbreaks like COVID-19, POAI is taking proactive measures to be part of the solution by applying artificial intelligence to aid in the development of new drugs and vaccines. Utilizing Soluble Therapeutics HSCTM technology and its six machines, Soluble's computer system expects to be able to run over 12,000 computer simulations per machine to help generate new diagnostics, vaccines and therapeutics. Solubles HSCTM technology has demonstrated efficacy with both new and existing vaccine and drug programs, ensuring the best delivery mechanisms to address new pandemics and battle cancers.

The market for biologicals that includes vaccines, proteins and antibodies used in disease treatment is projected to reach $479.7 billion by 2024 at a compound annual growth rate (CAGR) of 10.9%.* The capital the US Congress has allocated to fight COVID-19 is $8.0 billion dollars.

Protein formulation is often a bottleneck in protein-based drug development, and Soluble Therapeutics technology directly addresses this bottleneck.Combining the HSCTM technology with POAIs predictive modeling platform is expected to create a new rapid AI discovery platform that quickly and cost-effectively identifies potential therapeutic candidates. The HSCTM technology accelerates the formulation process and is believed to achieve in a month what can take a team of scientists several months to a year to achieve. The HSCTM technology only requires milligrams where a traditional formulation effort can require up to a gram of material.

HSC Technology is a self-contained, automated, chromatographic system that conducts high throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.

The HSC Instrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients and vaccine manufacturers, this means faster development times and quicker progression of molecules into the clinic. The COVID-19 vaccine development efforts by industry and government can benefit enormously using the Soluble HSCTM technology with POAIs predictive modeling platform.

Soluble hassix customized machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion. Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments, said Carl Schwartz, CEO of Predictive Oncology.

The combination of Soluble Therapeutics technology with Predictive Oncologys AI capability has the potential to rapidly optimize formulations thereby accelerating the early phase of protein therapeutic development, said Dr. Larry DeLucas, co-inventor of the HSC technology.

Under the operating agreement, the Company and existing Soluble managers will operate the Soluble Therapeutics business pending the acquisition. The Company's acquisition of Soluble Therapeutics is subject to the completion of a definitive agreement and customary closing conditions and is expected to close in the second quarter of 2020.

Story continues

*Global Biologics Market to touch US$479 Billion Dollars by 2024. Transparency Market Research. Feb 2018. Web.

About Predictive Oncology Inc.

Predictive Oncology (POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients specific needs. Predictive Oncologys TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially fools cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis Oncology Capture Technology Platforms which isolate and help categorize an individual patients heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncologys Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit http://www.predictive-oncology.com.

Forward-looking Statements

Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Companys business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) the risk that the acquisition ofSoluble Therapeuticswill not be completed, or, if completed, that the Soluble Therapeutics technology does not provide anticipated benefits to the Company or involves higher costs than anticipated or other negative consequences, (ii) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Companys and Helomics existing businesses, distraction of management and diversion of resources; and the market price of the Companys common stock may decline as a result of the merger; (iii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iv) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictives ability to implement its long range business plan for various applications of its technology; Predictives ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictives technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Companys reports filed with the SEC, which are available for review at http://www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictives financial position. See Predictives most recent Annual Report on Form 10-K, and subsequent reports and other filings at http://www.sec.gov.

Contact:Bob Myers651-389-4800bmyers@skylinemedical.com

Source: Predictive Oncology Inc.

See more here:
Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS,...

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A new kind of ink for 3D printing liquifies when pressed through the nozzle of a 3D printer, but then quickly returns to its original shape, researchers report.

The invention paves the way for personalized biomaterial implants, according to new research.

In the same way that medicine has seen a trend towards precision medicinewhere doctors tailor treatment to the genetic make-up of the patientin recent years, materials scientists have increasingly turned their attention to precision biomaterials. As things stand, however, personalized implants remain a long way off.

But at the moment, were making great progress toward this goaland learning a lot in the process, says Mark Tibbitt, a professor of macromolecular engineering in the mechanical and process engineering department at ETH Zurich.

Previously, the fact that researchers had to develop new [A1] inks for the 3D printer for each application held back researchers working in the field of precision biomaterials.

If someone wanted to replicate part of an eye, for instance, they werent able to draw on the work of people who design auricular prostheses, Tibbitt explains. But now, he and his team have invented a universal carrier ink that dramatically simplifies the development of new applications, the researchers write.

Essentially, 3D printing calls for a solution to a conundrum casually referred to as the toothpaste problem. On one hand, toothpaste should not be too viscous as that would make it difficult to squeeze through the narrow opening of the tube; on the other, it cant be too fluid because it would then immediately drip off the toothbrush.

Similarly, in 3D printing, the carrier ink needs to be able to liquify to flow through the printing nozzle, and then solidify so that the printed structure does not immediately lose its shape.

This is where the universal carrier ink that Tibbitts team has developed can help. It consists of cellulose fibers dissolved in water combined with biodegradable polymeric nanoparticles. When no external pressure is exerted, the fibers attach themselves to the particles. This creates a transient network that can be disrupted when subjected to the high shear forces in the printer nozzlebut that quickly reforms after passing through the narrow opening.

In further experiments, Tibbitt and his team added different polymers (such as hyaluronic acid, gelatine, collagen, or fibrinogen) to their new carrier ink. These secondary polymers did not change the inks flow behavior through the head of the printer nozzle, but enabled the researchers to solidify the transient network to form the printed structure in a second, subsequent step.

Tibbitts team also tested how living cells behave in the carrier inkand found that the same number of cells survive in the ink as they do outside. Based on the fact that researchers can introduce hydrophobic substances into the nanoparticlesand add hydrophilic substances to the aqueous phase with the cellulose fibersthey demonstrated that their ink is also suitable for the development of novel drug delivery systems.

The research appears in the journal Small.

Source: ETH Zurich

Read the rest here:
3D printing ink may solve the "toothpaste problem" - Futurity: Research News

Fifteen years and $2.5 billion dollars is too much to get a drug to market that many cannot even ... [+] afford. Solution: put big pharma in the cloud, and make drug discovery possible from a coffee shop.

Small biotech start-ups accounted for 63% of all new prescription drug approvals in the last five years. And the way that many big drug companies are establishing their own venture capital funds to invest in small, innovative start-ups, its easy to argue that big pharma isnt doing much innovation these days.

Whats going on here?

You can literally sit at a Starbucks, design a compound, have the robots assemble that compound and go through the purification and analysis steps to validate what youve made, Mark Fischer-Colbrie tells me. Hes the President and CEO of Strateos, and his company is taking all the processes, instruments, and robotics youd find in a big pharmaceutical R&D facility and making them accessible to anybody with a laptop and a good idea.

This is the lab of the future, where automated drug discovery can be done from the comfort of a coffee shop. The capital investments associated with traditional pharmaceutical research and development are gone. And perhaps most importantly for Fischer-Colbrie, this is the foundation biology needs to become industrialized.

Combining automation in biology and chemical synthesis while leveraging big data and machine learning, Strateos Robotic Cloud Lab is a platform for biological discovery at unprecedented speed, reproducibility, and cost-effectiveness.

Combining forces with Eli Lilly and Company, Strateos powers a robotic cloud laboratory that can compress a three-and-a-half year drug discovery cycle into 12 months. Open to a wide range of usersfrom big pharma through to synthetic biology and academiathe company has triggered a high-throughput revolution in life science.

If you look broadly across life sciences, I would estimate more than 90% of the workflows are manual, with uncertain data capture, say Fischer-Colbrie, reflecting on the status quo of most lab research today. In order to advance discovery, all of this needs to get industrialized, which means automation, it means repeatability.

A reproducible platform for better drug discovery

Therein lies a huge benefit for companies and consumers: the drastically improved reproducibility of Strateos automated workflows. Science is in the grips of a replication crisis. A Nature report not too long ago showed that 70% of academics had tried and failed to reproduce anothers experiment. One study of cancer research showed that the rate of converting preclinical cancer research to successful treatments was as low as 11%. The rate for drugs, in general, has previously been reported at somewhere around 25%.

The result of this? A long, wasteful, and expensive drug discovery process, with small numbers of expensive therapies available to patients.

To be in an environment that takes 15 years and $2.5 billion dollars to get a drug to market that no-one can pay for is a broken model that needs to be rectified, Fischer-Colbrie laments. And though there are various reasons for the lack of translation of science findings, reproducibility of the method is a huge component. Strateos platform provides the robust, automated design-make-test-analyze technology that can turn things around.

Fischer-Colbrie tells me that after youve designed a drug from the corner coffee shop, You then have the whole biological testing piece looking at dose-response curves, and all the other criteria youd need to make first level assessments of whether that compound might make a good therapy or not.

Fast-track cancer therapies

Strateos is a merger of Transcriptic and 3Scan. The former has a focus on high-throughput biology, and the latter focuses on making tissue biology and histopathology into data science. Combining these competencies within Strateos means the company well-suited to applying its technology platform for cancer.

Instead of spending the painstaking hours to prepare samples manually, you can take samples from a patient, slice them into micron-thin slices and deposit them automatically on a tape. You can then look at your 3D image and run a range of different analysesit might be some transcriptomics on slice 18, or immunohistochemistry on slice 19.

Tissue handling is a huge bottleneck currently, but this is a new way of getting data in a totally different manner, Fischer-Colbrie explains. The 3scan offering has the benefit of being able to generate new datasets that in turn you can then use the San Diego lab to come up with compounds that might work against what youve found in those tissue samples.

Focus on the concept

Strateos has created an entire life sciences discovery foundry, and one which is providing the necessary step to turn laboratories into data generation engines - launching biology as an information science.

Fischer-Colbrie enthusiastically stresses that it really allows scientists to focus on concept. Theyre not thinking about how to maintain equipment, or which company they have to negotiate complicated contracts with. Scientists can focus on their hypotheses and experiments and not the infrastructure or day to day worries in the lab.

Its a game-changer, and one that improves the quality of hypothesis-driven research in general.

You can watch experiments happen online, get the data rapidly, and feed into machine learning models that provide whole new hypotheses overall, notes Fischer-Colbrie, along with another crucial point. These data, importantly, also include metadata such as environmental conditions and the status of the equipment. So, if you get an anomalous result, you can go back and understand what was going on at the time.

A range of industries set to reap the rewards

In the short term, Strateos platform will be open to a range of potential uses across the life sciences, from big pharma through to personalized medicine and even work in large molecules such as antibodies.

In synthetic biology, in particular, Fischer-Colbrie is excited about the platforms ability to rapidly accelerate experiments and to optimize conditions for gene editing. Its stunning in the context of the ability here to turn ideas into data. We believe in some cases this can happen in as little as 48 hours. This will have a significant improvement in the cycle time of experimentation and design.

The world is gradually shifting from standalone instruments to automated work cells, and now we really have to think about data generation and how to analyze that data. He concludes. Were excited about how this will have an impact across the board.

Follow me on twitter at @johncumbers and @synbiobeta. Subscribe to my weekly newsletters in synthetic biology and space settlement.

Thank you to Peter Bickerton for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write aboutincluding Strateosare sponsors of the SynBioBeta conference and weekly digest heres the full list of SynBioBeta sponsors.

Excerpt from:
Running Your Pharma Company Out Of A Starbucks: Drug Discovery Moves To The Cloud - Forbes

Vetek (Seniority) the Movement for Longevity and Quality of Life (Israel)

Summary

Due to the aging of the global population and the derivative increase in major aging-related non-communicable diseases and their economic burden, there is an urgent international need to promote the research, development and application of and education on effective and safe therapeutic geroscience interventions. These interventions are designed to mitigate degenerative aging processes, thus preventing and eliminating the main underlying contributors for major chronic aging-related diseases and thus improving the healthy and productive longevity for the elderly population. Insofar as aging is the main contributing factor of major chronic age-related diseases, the research and development efforts in the fields of geroscience and of major chronic diseases are integrally related. Israel can be an important contributor to these international R&D efforts, for which it can offer its proven record of scientific and technological achievements and innovation, its strong supportive infrastructure for research and development, its highly skilled scientific and technological work force, including leadership in diverse branches of biomedical research on aging and aging-related diseases. Yet a stronger effort will be needed to build on those strengths and realize the countrys potential in the field for the benefit of the Israeli and global population. Israel can help further promote the field, not only locally, but internationally, by creating and sharing policy suggestions for the advancement of the field.

1. Israel has made significant progress in the fields related to geroscience and combat of major aging-related diseases.

Israel can and should be an important contributor to the global geroscience endeavors, building on its scientific, technological and societal achievements in the field of aging and related fields[1]:

Building on the past achievements, there is still a vital need to develop the geroscience and healthy longevity field in Israel, and there exists a large space for the growth of the field.

There are several specific pressing needs and demands for the development of the geroscience and healthy longevity field in Israel. The needs and the corresponding recommendations listed below closely follow the points made by the Vetek and allied associations in their recommendations for Enhancing research, development and education for the promotion of healthy longevity and prevention of aging-related diseases in the Israel National Masterplan on Aging. Yet, here they are given a wider international perspective, insofar as these needs and recommendations are quite common and applicable for virtually any country. Moreover, these needs and recommendations can be advocated and promoted via international frameworks and organizations, both globally and for specific countries on a case-by-case basis.

Today, there are about 980,000 people in Israel over the age 65 (about 11% of the countrys population), and it is expected that the number of the elderly will increase to 1.6 million by 2035. This reality demands the preparedness of the healthcare and welfare systems to provide worthy and sufficient services for the elderly, adequate solutions for the prevention of systemic economic and healthcare collapse, as well as for the equitable social inclusion of the elderly, and as a result the improvement of their quality of life and the countys economic growth. To achieve those goals, the advancement of medical research and development is a necessary condition. The aging-related health decline is the major cause of mortality, morbidity and disability. It is thus the root cause of all healthcare and economic challenges related to the population aging and should be addressed according to the severity of the problem. Therefore, considerable resources must be dedicated to the advancement of research, development and education aimed at the amelioration of degenerative aging processes and debilitating aging-related diseases in order to extend healthy longevity as much as possible for the entire population.

Yet, the investment of human and material resources in the field is still insufficient in Israel. Presently, the State of Israel expends only about 0.5% of its general research budget for the research of aging and aging-related diseases (just about $5M dedicated annual state budget). Except for the budget framework for science, technology and innovation for the older persons within the Ministry of Science and Technology, there are no other defined budget frameworks in Israel for research and development in the field of aging, healthy longevity and prevention of aging-related diseases. There are limited support frameworks that can be adapted to the subject, such as research budgets for specific diseases, such as Alzheimer's disease, diabetes, cancer, etc., which by their nature are aging-related diseases. But in fact, there are no dedicated support frameworks specifically addressing aging-related ill health as a whole (old-age multimorbidity), neither addressing aging as the primary contributing factor for age-related diseases, and there is almost no reference to the special medical needs and characteristics of the aging individuals and the older population. Their characteristics and medical needs are often dramatically different in terms of diagnosis and treatment from the younger population, and the difference may have a decisive impact on the effectiveness of treatment. There is also a lack of centralized R&D support frameworks for the field of aging in Israel, such as the NIH's National Institute on Aging that exists in the US.

Therefore, defined budget frameworks must be established for medical research and development that will specifically address the issue of aging, and promote healthy longevity and prevention of aging-related diseases. Specifically, a defined significant percentage of the research and development budgets of the relevant ministries must be dedicated to the field. These should include the Ministry of Health; the Ministry of Science and Technology; the Planning and Budgeting Committee of the Council for Higher Education; the Israel Innovation Authority; the Israel Science Foundation; the Israel Academy of Sciences and Humanities including the National Infrastructure Forum for Research and Development; the Ministry for Social Equality; the National Insurance Institute; the bi-national and international research programs in which Israel is a partner, particularly in the divisions concerning the research and treatment of non-communicable chronic diseases.

These frameworks must provide funding for calls for research proposals, grants, scholarships, services and action plans designed to alleviate the degenerative aging process and improve the longevity and quality of life of the older population, on behalf and in cooperation of the relevant ministries and institutions.

There is a now a severe deficit of relevant educational materials of any kind in Israel, in the field of aging generally, and particular areas of geroscience and healthy longevity promotion in particular. Currently, aging research is severely under-represented in all academic and other educational frameworks. Good education may be considered a primary condition for progress. There is a need to address the large deficit of knowledge and training on the subject of biological aging, its biomedical improvement and healthy longevity, in most existing institutions of learning. The need should be obvious. It should be clear that prior to any research, development and application on biological aging, there is a need to educate specialists who will be able to contribute to the various aspects of the field. There is an even prior need to educate the broader public on the importance of such research to prepare the ground for further involvement.

Such education is currently very limited. In practical terms, there are presently rather few dedicated structures in Israel to promote and coordinate knowledge exchange and dissemination on biological aging and healthy longevity promotion. There is an urgent necessity for such educational structures to make the narrative on biology of aging and healthy longevity prevalent in the public and academic discourse. To improve the communication and integration, it appears to be crucially important to commonly include the subjects of biogerontology, geroscience and healthy longevity promotion as central parts of learning curricula, and not only in universities, but in every learning and teaching framework, especially those related to biology, medicine or natural sciences generally. Yet, unfortunately, and strangely enough, the study of the biology of aging and longevity is rarely a part of university curriculum and virtually never a part of high school or community education curriculum. Thus, there is a vast range of opportunities to develop educational and training materials and courses, including materials and courses of professional interest, from undergraduate to postgraduate levels, as well as of general interest, presenting recent advances in aging and longevity science. Educational teaching and training materials on the subject should be developed and disseminated for people at all education levels, both for the academia and the general public, for all age groups, for different sectors and in different languages, in accordance with their specific abilities and characteristics. Teaching programs that increase motivation and stimulate scientific thinking in the field should be developed for children, university students at different study stages (undergraduate and graduate), for interns and specialists, and as a part of adult enrichment studies.

In particular, it is necessary to develop study materials, such as courses, text books, problem solvers, guidelines and professional specialization programs in the biology of aging, especially for physicians and biologists in the fields adjacent to aging research, as well as educational materials for the general public. The materials for the general public should include lectures, reviews of the latest scientific developments in the field and practical recommendations for the promotion of healthy longevity and for the preparation of the younger generation to the challenges that expect them. There must be prepared and disseminated authoritative, evidence-based information about lifestyle regimens (such as nutrition, physical activity and rest) that promote healthy longevity and prevent aging-related ill health. A variety of educational teaching and training means should be developed, including conferences, printed materials, knowledge competitions, interactive web platforms, games and other accessible technological means. Relevant ministries and institutions should be involved in the development of and providing access to these educational programs, from the Ministry of Education and the Council for Higher Education to local authorities, public associations, and community centers. In order to facilitate the progress, there is a need to encourage the establishment of educational pilots and the examination of good practices in relevant ministries and other institutional frameworks.

One of the primary specific needs to develop the geroscience field, in Israel and elsewhere, appears to be the establishment of agreeable, scientific evidence-based evaluation criteria for the efficacy and safety of geroprotective (geroscience or healthspan-enhancing) therapies. Such commonly agreed evaluation criteria are presently lacking, in Israel and elsewhere. Yet, they appear to be absolutely necessary in order to set up the end points for the development of geroscience-based therapies and diagnostics and provide value-based incentives for academic, public and commercial R&D entities involved in the field. The field of geroscience is predicated on the recognition of aging as a major contributing and modifiable factor of pathogenesis, including such recognition in regulatory and budgeting frameworks. Yet, it appears that the primary necessary requirement for the degenerative aging process to be recognized as such a modifiable factor and therefore an indication for research, development and intervention, is to develop evidence-based diagnostic evaluation criteria and definitions for degenerative aging and for the efficacy and safety of potential means against it[17]. Without such scientifically grounded and clinically applicable diagnostic evaluation criteria and definitions, the discussions about treating, postponing, intervening into or even curing degenerative aging processes will be mere slogans. It appears to be impossible to treat, postpone, intervene into or cure a condition that it is impossible to diagnostically evaluate and measure the effectiveness and safety of treatment. Such evaluation criteria and measurements would need to become the basis for public geroscience-oriented health programs designed for the prevention of aging-related diseases, while measuring the effectiveness and safety of the interventions.

Therefore, it is necessary to develop and implement improved evaluation measures and criteria for assessing the aging process, for the early diagnosis and prediction of multiple aging-related diseases (old-age multimorbidity), for examining the effectiveness of treatments for their prevention and for estimating and improving the older persons functional and employment abilities. Commonly agreed, science-based and authoritative guidelines should be provided for such measures by authoritative and representative national and international organizations. To develop such measures, it is necessary to increase and improve the collection and processing of various types of data on aging, including biological and medical data in combination with behavioral and social, economic and environmental data. In this process, it is necessary to establish and/or expand relevant databases (registries) and analytical platforms and tools (knowledge centers) in order to facilitate the collection, design, accessibility, analysis, integration and sharing of data on aging, promotion of healthy longevity and prevention of aging-related diseases. These databases and analytical tools should be used predictively to model large amounts of data for more effective diagnosis and treatment and to allow personalized medicine for the older subjects, with reference to their aging process.

In Israel, in order to establish and expand these measurement and analysis systems, it is necessary to involve the relevant ministries and institutions, in particular the Ministry of Health, with the maximum possible cooperation of other entities who have access to data on aging, such as research institutions, hospitals, health maintenance organizations, local authorities and public and commercial research communities. The goals of evaluating the aging processes, early detection and prevention of aging-related ill health as a whole (preventing old-age multimorbidity) and extension of healthy lifespan, should be specifically defined in relevant frameworks and programs, such as the National Program for Personalized Medicine and the National Program for Digital Health, as well as relevant international health promotion programs where Israel takes part. Initiatives and pilots of different extents on the subject should be encouraged in all sectors, while supporting their cooperation.

The above needs and demands for the development of the geroscience and healthy longevity field, directly yield policy recommendations for the fields advancement. Currently, official policy recommendations for the promotion of the geroscience and healthy longevity field are lacking in most major international as well as national frameworks. Such recommendations, for both international and national policy frameworks, must be developed and advocated by authoritative and representative international organizations promoting geroscience research and education.

An exemplary effort to develop and advocate such policy recommendations is the position paper of the International Society on Aging and Disease (ISOAD), entitled The Critical Need to Promote Research of Aging and Aging-related Diseases to Improve Health and Longevity of the Elderly Population (2015)[18]. This position paper makes the general appeal that Governments should ensure the creation and implementation of the policies to promote research into the biology of aging and aging-related diseases, for improving the health of the global elderly population. It further provides specific policy suggestions with reference to enhancing funding, institutional support and incentives for biomedical aging research. This position paper has been translated to 12 languages and submitted for consideration to several governments. It has stimulated further discussion, encouraging the academic community, the general public and decision makers to elaborate on the policies to support the aging R&D field[19].

Such position papers and consultations can have tangible effects on public health policy and research policy, as evidenced by another position paper, jointly advanced by the International Society on Aging and Disease, American Federation for Aging Research, International Federation on Aging, International Association of Gerontology and Geriatrics and other leading organizations on aging, entitled Aging health and R&D for healthy longevity must be included into the WHO Work Program (2018)[20]. Largely thanks to this position paper and the associated advocacy campaign, the subject of healthy aging that had been originally absent, was eventually included into WHOs 13th General Programme of Work for 2019-2023, including specific end points for the reduction of elderly disability and increasing their healthy life expectancy. The contribution of this advocacy campaign was acknowledged by the director of the WHO Ageing and Life Course Division[21]. Another position paper followed the recent establishment of the UNESCO-affiliated Executive Committee on Anti-Aging and Disease Prevention, entitled The urgent need for international action for anti-aging and disease prevention[22].

These are preliminary examples, and more of such position papers, guidelines and advocacy efforts are needed to advance the geroscience and healthy longevity field, both at the national and international levels. Authoritative and representative international organizations should take on this work, preparing and advocating policy suggestions and guidelines, creating educational materials and providing platforms for scientific cooperation in the geroscience and healthy longevity field.

Specifically, building on the experience of the Israeli program for Enhancing research, development and education for the promotion of healthy longevity and prevention of aging-related diseases within the Israel National Masterplan on Aging (see the previous section), such international organizations may consider advancing the following activities and policies, within specific countries and globally:

International organizations should advocate for a significant increase in the level of governmental and non-governmental funding for basic, applied, translational and clinical research and technological development for the mitigation of degenerative aging processes, aging-related chronic non-communicable diseases and disabilities, in order to extend the healthy and productive life expectancy for the entire population throughout the entire life course. Specifically, the international organizations should advocate for the allocation of defined significant percentages of the research and development budgets of the relevant budgeting frameworks to be dedicated explicitly for the geroscience and healthy longevity field, including bi-national and international research and development programs.

International organizations should create and expand academic and public education frameworks, programs and educational materials, considering the basic and applied research on aging processes and aging-related diseases, promoting healthy longevity, preventing aging-related diseases and improving the quality of life for the elderly, including biological, medical, technological, environmental and social aspects.

International organizations should develop and implement and/or advocate for the development and implementation of evidence-based evaluation criteria, measures and indicators to estimate the effects of aging, predict and detect at an early stage multiple aging-related diseases, and examine the effectiveness and safety of therapeutic and preventive interventions against them. Concomitantly, evaluation criteria, measures and indicators must be developed and advanced for the functional and employment capacity of the elderly and for the improvement of their functional capacity. Such evaluation criteria, measures and indicators should be used for establishing and/or improving public health systems for the early detection and prevention of degenerative aging processes and aging-related diseases.

Combined, these measures and policies should advance the geroscience and healthy longevity field, nationally and internationally, for the benefit of the elderly and the entire population.

References

[20] Stambler I, Jin K, Lederman S, Barzilai N, Olshansky SJ, Omokaro E, Barratt J, Anisimov VN, Rattan S, Yang S, Forster M, Byles J (2018). Aging health and R&D for healthy longevity must be included into the WHO Work Program. Aging and Disease, 9(2): 331-333 http://www.aginganddisease.org/article/2018/2152-5250/ad-9-2-331.shtml.

Ilia Stambler is an IEET Affiliate Scholar. He completed his PhD degree at the Department of Science, Technology and Society, Bar-Ilan University. His thesis subject, and his main interest, is the History of Life-extensionism in the 20th Century.

See the rest here:
Israel can and should become an important contributor to the international geroscience research, development, application and education - Institute...